An FDA advisory panel declined to endorse the Ventura interatrial shunt system, a heart failure device developed by V-Wave, a Johnson & Johnson company, according to a Dec. 5 TCTMD report. Panel ...

TUCSON, Ariz. (KVOA) - Carondelet St. Mary’s Hospital has achieved a milestone by completing its first procedure to implant the Barostim™ Baroreflex Activation Therapy device. This innovative heart ...

The phase 2 trial showed that coramitug, an antibody targeting misfolded transthyretin in ATTR-CM, was well tolerated. A dose of 60 mg/kg resulted in a statistically significant reduction in NT-proBNP ...

Two Sarepta Therapeutics drugs for treating different genetic subsets of patients with Duchenne muscular dystrophy failed the confirmatory study required of their accelerated FDA approvals. Sarepta ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min VisCardia will soon be enrolling ...

Edesa Biotech has shared data from its truncated phase 3 respiratory failure trial, linking the anti-TLR4 antibody to improvements in survival and recovery. The trial enrolled about 100 people who ...

Medical devices are true marvels of human ingenuity. They save lives and improve quality of life in countless ways. But what happens when the materials used to make them can't keep up? In vascular ...

Texas Instruments Inc. (TI) announced several power management devices and a reference design to help companies meet AI computing demands and scale power management architectures from 12 V to 48 V to ...

Georgia Power, in partnership with Switched Source and ARPA-E, has installed the Phase-EQ device in Macon to increase power line capacity by up to 20%, reduce load and voltage imbalances, and enhance ...

MINNEAPOLIS -- The novel dual-function cardiac contractility modulation-defibrillator (CCM-D) for heart failure with reduced ejection fraction (HFrEF) had favorable early results in the Integra-D ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...